AI in Cancer Diagnostics Market by Component, Deployment, Cancer Type, End-user

Description

List of Tables

The AI in Cancer Diagnostics Market was valued at USD 220.38 million in 2023, expected to reach USD 266.28 million in 2024, and is projected to grow at a CAGR of 21.52%, to USD 862.50 million by 2030.

The scope of AI in cancer diagnostics spans the integration of advanced algorithms and machine learning techniques to enhance early detection, diagnosis accuracy, and personalized treatment strategies. The necessity of AI arises from the growing cancer burden and the need for more precise and faster diagnostic methods. Applications range from image analysis to predicting treatment outcomes, significantly impacting end-users such as hospitals, research institutions, and diagnostic labs. Market growth is fueled by technological advancements in AI, increased healthcare expenditure, and growing awareness of personalized medicine. However, data privacy concerns, high costs, and lack of standardized regulations pose significant challenges. Despite these barriers, the latest opportunities include developing AI-driven tools for real-time cancer detection and integrating AI with other technologies such as genomics for comprehensive diagnostics. Companies are recommended to invest in research collaborations to enhance AI models' accuracy and applicability across diverse populations, addressing current biases and limitations. Innovation opportunities lie in creating AI systems that utilize big data for predictive analytics, enhancing workflow efficiency in diagnostic processes, and improving patient outcomes. Additionally, there is a promising avenue for creating AI platforms that facilitate data sharing among healthcare providers while ensuring patient confidentiality, potentially revolutionizing collaborative care models. Research into ethical AI usage and transparent AI user interfaces could further enhance trust and adoption rates. The market is dynamic yet competitive, driven by rapid technological progress and evolving healthcare needs, requiring stakeholders to stay agile and responsive to new trends. An integrated strategy combining technological innovation, compliance adherence, and strategic partnerships can unlock significant potential in AI for cancer diagnostics, offering substantial growth and development opportunities in this crucial sector.

KEY MARKET STATISTICS
Base Year [2023]	USD 220.38 million
Estimated Year [2024]	USD 266.28 million
Forecast Year [2030]	USD 862.50 million
CAGR (%)	21.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving AI in Cancer Diagnostics Market

The AI in Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Prevalence of cancer among the global population
- Proliferating adoption in several cancer screening programs worldwide
- Exponential shift towards non-invasive cancer diagnosis
Market Restraints
- High cost and shortage of trained oncologists
Market Opportunities
- Technological improvements in cancer diagnostics
- Government investments in using AI in cancer diagnostics and treatments
Market Challenges
- Vulnerability to cyberattacks and data breaches

Porter's Five Forces: A Strategic Tool for Navigating the AI in Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the AI in Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the AI in Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the AI in Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the AI in Cancer Diagnostics Market

A detailed market share analysis in the AI in Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the AI in Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the AI in Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the AI in Cancer Diagnostics Market

A strategic analysis of the AI in Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.

Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Component, market is studied across Hardware, Services, and Software.
Based on Deployment, market is studied across Cloud and On-Premise.
Based on Cancer Type, market is studied across Brain Tumor, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Skin Cancer.
Based on End-user, market is studied across Cancer Centers and Hospitals.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-B16853776A7C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of cancer among the global population
  - 5.1.1.2. Proliferating adoption in several cancer screening programs worldwide
  - 5.1.1.3. Exponential shift towards non-invasive cancer diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. High cost and shortage of trained oncologists
- 5.1.3. Opportunities
  - 5.1.3.1. Technological improvements in cancer diagnostics
  - 5.1.3.2. Government investments in using AI in cancer diagnostics and treatments
- 5.1.4. Challenges
  - 5.1.4.1. Vulnerability to cyberattacks and data breaches
5.2. Market Segmentation Analysis
- 5.2.1. Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
- 5.2.2. Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. AI in Cancer Diagnostics Market, by Component

6.1. Introduction
6.2. Hardware
6.3. Services
6.4. Software

7. AI in Cancer Diagnostics Market, by Deployment

7.1. Introduction
7.2. Cloud
7.3. On-Premise

8. AI in Cancer Diagnostics Market, by Cancer Type

8.1. Introduction
8.2. Brain Tumor
8.3. Breast Cancer
8.4. Colorectal Cancer
8.5. Lung Cancer
8.6. Prostate Cancer
8.7. Skin Cancer

9. AI in Cancer Diagnostics Market, by End-user

9.1. Introduction
9.2. Cancer Centers
9.3. Hospitals

10. Americas AI in Cancer Diagnostics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific AI in Cancer Diagnostics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa AI in Cancer Diagnostics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
- 13.3.2. ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
- 13.3.3. Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Aiosyn B.V.
2. Cancer Center.ai
3. ContextVision AB
4. Deep Bio Inc.
5. Google LLC by Alphabet Inc.
6. Ibex Medical Analytics Ltd.
7. International Business Machines Corporation
8. Kheiron Medical Technologies Limited
9. Lifebit Biotech Ltd
10. Lunit Inc.
11. Medial EarlySign
12. Microsoft Corporation
13. Mindpeak GmbH
14. Paige AI, Inc.
15. PathAI, Inc.
16. Proscia Inc.
17. Qritive
18. Quantib B.V.
19. ScreenPoint Medical BV
20. Siemens Healthineers AG
21. Tempus Labs, Inc.
22. Therapixel
23. Visiopharm A/S
24. Viz.ai
25. Xavor Corporation